關於 takeda dengue vaccine ，我們在網路上蒐集到這些相關的討論、資訊與評價

#11. Takeda's dengue shot keeps 84% of kids out of hospital ...

The two-dose vaccine was 62.0% effective at preventing dengue infection three years after participants received the second dose, the latest data show. That's ...

#12. Takeda Vaccines

Takeda is taking steps towards making an impact on public health by developing ... About 50% of the world's population lives under the threat of dengue, ...

#13. Takeda in talks to bring its dengue shot to India - The ...

India is not a part of the global Phase-3 trial of the Takeda dengue vaccine candidate, which means as per local regulation it will have to ...

#14. Planning ahead for access to the dengue vaccine

Takeda has strong project-specific access plans for some late-stage R&D projects. One such project is its dengue vaccine (TAK-003). Takeda intends to file for ...

#15. Takeda eyes vaccine business growth as dengue, COVID-19 ...

Takeda's dengue fever vaccine was submitted to European regulators in March, and the company said it planned to file for approval in several ...

#16. Takeda's dengue vaccine bags positive long-term efficacy ...

Japanese pharma company Takeda has announced that its dengue vaccine candidate TAK-003 demonstrated continued protection through three years ...

#17. After Sanofi's setbacks, Takeda eyes finish line with its dengue ...

Takeda has revealed long-term clinical trial results with its dengue vaccine that reinforce its safety and efficacy – and help to ...

#18. GDAC statement on Takeda's announcement about their ...

Yesterday, Takeda Pharmaceutical Company Limited announced their live-attenuated tetravalent dengue vaccine candidate, designated as TAK-003, ...

#19. Takeda Still Hopeful On Dengue Vaccine Candidate - Pink ...

Takeda Pharmaceutical hopes to find out by the end of fiscal year 2021 whether its tetravalent dengue vaccine candidate, TAK-003, is likely to ...

#20. For India, Finally A Dengue Vaccine In Sight | Mint

Takeda is in talks with the Indian drug regulator to seek approval for its dengue vaccine, which has been shown to prevent hospitalizations ...

#21. (PDF) Three-year Efficacy and Safety of Takeda's Dengue ...

PDF | Background: Takeda's live attenuated tetravalent dengue vaccine candidate (TAK-003) is under evaluation in a long-term clinical trial ...

#22. Long-Term Study Reaffirms Potential of Takeda's Dengue ...

Takeda has touted the potential of its Dengue vaccine for several years, and new long-term data reinforces the promise of the medication ...

#23. Three years efficacy and safety of Takeda's ... - Europe PMC

Takeda's live attenuated tetravalent dengue vaccine candidate (TAK-003) is under evaluation in a long-term clinical trial across eight ...

#24. Takeda's dengue vaccine efficacious, decreases ...

Takeda's live attenuated tetravalent dengue vaccine candidate (TAK-003) will be the first dengue vaccine to be cleared for use in India if ...

#25. EMA accepts submission for Takeda's dengue vaccine ...

TAK-003 is a tetravalent dengue vaccine candidate based on a live-attenuated dengue serotype 2 virus, which provides the genetic backbone for ...

#26. Dengue vaccine - Wikipedia

Dengue vaccine is a vaccine used to prevent dengue fever in humans. Development of dengue vaccines began in the 1920s, but was hindered by the need to ...

#27. New dengue vaccine performs well in large trial, but safety ...

Unlike Sanofi's efficacy trials of Dengvaxia, Takeda assessed, prevaccination, whether participants in its study had antibodies from a previous dengue infection ...

#28. Takeda's dengue vaccine prevents hospitalisations in TIDES ...

Takeda's tetravalent dengue vaccine candidate, TAK-003, offers protection against hospitalisation and illness in Phase III trial. ... TAK-003 ...

#29. Efficacy of a Tetravalent Dengue Vaccine in Healthy Children ...

TAK-003 was efficacious against symptomatic dengue in countries in which the disease is endemic. (Funded by Takeda Vaccines; TIDES ...

#30. Dengue Vaccine: Takeda Reports Promising Results

In a press release, Takeda announced that its vaccine candidate, TAK-003, reduced illnesses from dengue by 62% and prevented 83.6% of ...

#31. The Lancet publishes papers from two studies of Takeda's ...

Takeda's dengue vaccine candidate is not currently licensed anywhere in the world. The DEN-204 study enrolled 1,800 participants.

#32. Dengue endemic vaccines: awaiting Takeda's TAK-003

A Sanofi Pasteur vaccine (CYD-TDV Dengvaxia®) has been licensed since 2015 for the prevention of disease caused by all four dengue virus ...

#33. Takeda's largest study brings dengue vaccine step closer

Japan's Takeda Pharmaceutical said on Wednesday it had completed enrolment for a 20000-subject dengue vaccine trial.

#34. Takeda's dengue vaccine appears effective, but the story is ...

In the wake of controversy over a Sanofi dengue vaccine, Takeda Pharmaceuticals is betting its own effort will meet a largely unmet medical ...

#35. Takeda's dengue data spell more bad news for Sanofi | Evaluate

A mass immunisation programme in the Philippines uncovered a link between the vaccine and more severe disease seen in previously uninfected ...

#36. Moving forward with Takeda's live chimeric tetravalent dengue ...

Vaccine efficacy estimates vary by previous seropositivity against dengue, infecting serotype, clinical severity, and age, of which previous ...

#37. Limited Transmission Potential of Takeda's Tetravalent ...

Limited Transmission Potential of Takeda's Tetravalent Dengue Vaccine Candidate by Aedes albopictus. Elizabeth A. Dietrich,1 Yee Tsuey Ong,1 ...

#38. Takeda's TAK-003 dengue vaccine candidate succeeds in ...

Takeda investigational dengue vaccine (TAK-003) candidate has achieved the primary endpoint in the pivotal phase 3 efficacy trial.

#39. The Takeda dengue vaccine: Promising results bring hope for ...

Professor Duane Gubler is one of the world's leading experts on dengue vaccines. He has supported the development of all three of today's ...

#40. Dengue Vaccine Candidate Reinforced by Long-Term Safety

REPUBLIKA.CO.ID, JAKARTA -- Takeda Pharmaceutical Company Limited (Takeda) announced that its dengue vaccine candidate (TAK-003) ...

#41. Takeda Completes Enrollment of More Than 20,000 Children ...

About TAK-003 Takeda's tetravalent dengue vaccine candidate (TAK-003) is based on a live-attenuated dengue serotype 2 virus (DENV-2), ...

#42. Dengue Outbreak in the Philippines Exceeds 52000 Cases ...

Takeda dengue vaccine candidate TAK-003 is in phase 3 clinical trial.

#43. Dengue vaccine from Takeda shows promise - News-Medical

Results from the vaccine trial showed that the vaccine was 80 percent effective in preventing dengue infections among the included participants ...

#44. Takeda plans German plant to support dengue vaccine roll-out

Takeda is investing more than €100m in a manufacturing facility in Germany that will produce its vaccine for dengue fever.

#45. Takeda to invest more than €100m in manufacturing plant for ...

The tetravalent dengue vaccine candidate TAK-003 is based on a live-attenuated dengue serotype 2 virus (DENV-2), which provides the genetic ' ...

#46. Takeda's Dengue vaccine candidate reveals protection in ...

Results demonstrated overall vaccine efficacy of 80.2% (12-month follow-up after second dose) against virologically confirmed dengue; ...

#47. Takeda's dengue vaccine said effective overall in study but ...

Takeda Pharmaceutical Co.'s experimental dengue vaccine was highly effective at preventing the mosquito-borne disease in a late stage study, ...

#48. Dengue vaccine: Takeda enrolls 20,000 children and ...

In Phase 1 and Phase 2 studies, Takeda's vaccine candidate induced neutralizing antibody responses against all four dengue virus serotypes ...

#49. Potential Impact of Takeda's Dengue Vaccine Candidate Reinforced ...

“Results from the long-term analysis of Takeda's dengue vaccine candidate suggest that it could help with outbreak prevention, reduce rates of hospitalization ...

#50. ICTRP Search Portal

Primary sponsor: Takeda. Public title: Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy ...

#51. Takeda to invest more than 100 million Euros in ... - bionity.com

“This manufacturing plant investment reinforces Takeda's strong support for our global vaccine strategy in general, and dengue in particular ...

#52. Takeda building Dengue fever vaccine plant - BioPharma ...

Takeda has started work on a vaccine plant to make its candidate Dengue fever virus vaccine, TAK-003.

#53. Hopeful results from trials of dengue vaccine candidate

Phase 2 and 3 randomized, controlled clinical trials of Takeda's tetravalent (four-strain) dengue vaccine candidate show that it is safe, ...

#54. New Dengue Vaccine Shows Promising Clinical Results

Takeda Pharmaceutical's experimental dengue vaccine has produced promising long-term results in clinical tests, boosting the Japanese ...

#55. Takeda Begins Regulatory Submissions for Dengue Vaccine ...

Takeda's tetravalent dengue vaccine candidate (TAK-003) is based on a live-attenuated dengue serotype 2 virus, which provides the genetic “ ...

#56. 3-year mark for Takeda Dengue vaccine: efficacy remains with ...

Takeaway. Ongoing data demonstrate TAK-003 vaccine candidate efficacy against symptomatic dengue virus (DENV) in both children and ...

#57. With its dengue vaccine in the regulatory queue, Takeda ...

The protection that the vaccine offers has waned across the board compared to the last cut of data at 18 months, when Takeda touted an overall ...

#58. Takeda opens new dengue vaccine manufacturing plant in ...

In November this year, the Japanese pharmaceutical firm Takeda inaugurated its first dengue vaccine manufacturing plant in Singen, Germany.

#59. Takeda's dengue vaccine meets primary endpoint in Phase III

Take a look at this month's industry headlines including clinical trial results for a dengue vaccine and new funding for CRSIPR-based ...

#60. Dengue vaccine: India enters the global race

Later, the US National Institutes of Health developed a vaccine candidate with a natural dengue virus, plus deletions to ensure it did not cause ...

#61. EMEA-001888-PIP01-15-M01 | European Medicines Agency

Prevention of dengue fever. Route(s) of administration. Subcutaneous use. Contact for public enquiries. Takeda Vaccines, Inc.

#62. Takeda Completes Enrollment of Large Global Phase 3 Trial ...

In Phase 1 and Phase 2 studies, Takeda's vaccine candidate induced neutralizing antibody responses against all four dengue virus serotypes ...

#63. Study demonstrates long-term safety, immunogenicity ... - Healio

A tetravalent dengue vaccine candidate elicited long-term immune responses in ... vice president and global dengue program leader at Takeda, ...

#64. Takeda Unveils New Dengue Vaccine Manufacturing Plant in ...

Takeda's tetravalent dengue vaccine candidate (TAK-003) is based on a live-attenuated dengue serotype 2 virus, which provides the genetic “ ...

#65. ACIP Dengue Vaccines Workgroup Considerations and ... - CDC

Address reprint requests to Dr. Biswal at Takeda Vaccines, 21 Biopolis Rd.,. Nucleos, Level 4, Singapore 138567,. Singa- pore,.

#66. Takeda to invest more than 100 Million Euros in Dengue ...

“This manufacturing plant investment reinforces Takeda's strong support for our global vaccine strategy in general, and dengue in particular ...

#67. Dengue Vaccines: Current Status and Future Prospects - JCDR

developed by Takeda, Osaka, Japan [12]. This live-attenuated tetravalent dengue vaccine consists of a chimera of all four dengue.

#68. Takeda's dengue vaccine candidate demonstrates protection ...

New England Journal of Medicine publishes primary endpoint analysis from ongoing Phase 3 study of Takeda's dengue vaccine candidate.

#69. Potential Impact of Takeda's Dengue ... - Business Wire India

Takeda's tetravalent dengue vaccine candidate (TAK-003) is based on a live-attenuated dengue serotype 2 virus, which provides the genetic “ ...

#70. Takeda's Dengue Vaccine Demonstrates Long-Term Promise ...

Takeda Pharmaceutical's dengue vaccine candidate, TAK-003, offered strong continued protection against dengue fever, especially infection ...

#71. Takeda's Dengue Vaccine Candidate

Dengue disease. 2. Dengue in Australia. 3. Development of Takeda's dengue vaccine candidate. 4. Overview of ongoing and completed clinical studies.

#72. Potential Impact of Takeda's Dengue Vaccine Candidate ...

Potential Impact of Takeda's Dengue Vaccine Candidate Reinforced by Long-Term Safety and Efficacy Results − Takeda's dengue vaccine ...

#73. Takeda to Submit Regulatory Filing for New Dengue Vaccine ...

The vaccine phase II trial had shown the vaccine managed to induce immune responses against four viruses, called serotypes 1-4, that caused ...

#74. Takeda files long-term dengue vaccine data to support EU ...

New three-year safety and efficacy data on Takeda Pharmaceutical Co. Ltd.'s dengue vaccine candidate, TAK-003, showed it to be 62% more ...

#75. Takeda Says Its Dengue Vaccine Candidate Prevents Illness ...

Takeda's dengue vaccine candidate (TAK-003) prevented 83.6% of hospitalisations and 62.0% of dengue illness overall, with no identified ...

#76. Immunogenicity and safety of a tetravalent dengue vaccine in ...

A new tetravalent dengue vaccine candidate, TAK-003. (Takeda), is based on a live attenuated DENV-2 virus that pro-.

#77. Dengue Vaccine Candidate Provides 62% Efficacy for ...

TAK-003, from Takeda, is showing slightly improved protection among seropositive participants through its 36-month follow-up. dengue vaccine. A ...

#78. Takeda Symposium | Asian Dengue Voice and Action - ADVA ...

PH needs vaccine for dengue as disease remains a threat despite drop in cases. July 4, 2021. MANILA, Philippines — Dengue fever cases ...

#79. Takeda dengue vaccine candidate show long term safety ...

Takeda's dengue vaccine candidate prevented 83.6% of hospitalisations and 62% of dengue illness overall, with no identified important safety ...

#80. Dengue vaccine development: Global and Indian scenarios

A limited-use live attenuated dengue vaccine has been licensed since 2015. ... dengue vaccine (TetraVax-DV) and Takeda's tetravalent dengue ...

#81. Takeda signals global ambitions with dengue vaccine trial

Takeda, the largest Japanese drug group, has begun an extensive clinical trial of a vaccine against dengue, a mosquito-borne disease, ...

#82. Takeda expects to launch a better dengue vaccine - Nikkei Asia

Q: How is the development of Takeda's dengue vaccine faring so far? Why is Takeda focusing on this particular disease?

#83. Takeda dengue vaccine meets main goal of clinical trial

CHICAGO--Takeda Pharmaceutical Co. said on Tuesday that its experimental dengue vaccine appears to be safe and effective at preventing all ...

#84. Promising Results For Takeda's Dengue Vaccine - Asian ...

Takeda's dengue vaccine has proven to be safe and able to produce an antibody response against all four serotypes of dengue in an interim ...

#85. Takeda's Dengue Vaccine Shows Promise - WSJ

Takeda Pharmaceutical Co. TAK 0.39%△ released data from a large late-stage study Saturday showing that its experimental dengue vaccine was ...

#86. Takeda Pharmaceutical's dengue vaccine shows promise in ...

Japanese drugmaker Takeda Pharmaceutical Company Limited has said that its dengue vaccine candidate demonstrated protection against ...

#87. Takeda's dengue vaccine meets goal in Phase 3 study

Takeda's dengue vaccine met its primary goal in the first part of a Phase 3 study testing the treatment's ability to prevent the ...

#88. Partha's Immunization Digest - 第 379 頁 - Google 圖書結果

... 193 T Tabletop simulation 248 Takeda's dengue vaccine 226 Tetanus 26, 206 and diphtheria acellular pertussis 267 and acellular pertussis vaccination 67 ...

#89. New dengue vaccine effective in clinical trials - Asia & Pacific

“Takeda's dengue vaccine candidate was generally well tolerated, and no important safety risks have been observed to date.”.

#90. Human Virology in Latin America: From Biology to Control

The Takeda tetravalent dengue vaccine (TDV), in its turn, was constructed by using the life-attenuated DENV2 derived by serial passages of wild-type virus ...

#91. The APRN and PA’s Complete Guide to Prescribing Drug Therapy ...

Progress in development of Takeda's tetravalent dengue vaccine candidate. Paper presented at the 66th annual meeting of the American Society of Tropical ...

#92. Dengue clinches Takeda deal | Nature Biotechnology

Takeda Pharmaceutical of Osaka, Japan, has acquired vaccine developer Inviragen, a biotech company specializing in innovative vaccines for ...

#93. The APRN's Complete Guide to Prescribing Drug Therapy 2019

Progress in development of Takeda's tetravalent dengue vaccine. ASTMH 2017. Paper presented at the 2017 American Society of Tropical Medicine & Hygiene ...

#94. Takeda's Dengue Vaccine Effective Overall in Study but With ...

CHICAGO (Reuters) - Takeda Pharmaceutical Co's experimental dengue vaccine was highly effective at preventing the mosquito-borne disease in ...

#95. Takeda Opens Dengue Vaccine Plant in Germany - BioPharm ...

Takeda Pharmaceutical Company opened a new manufacturing plant in Singen, Germany, for its dengue vaccine candidate, TAK-003, ...

#96. Takeda (@TakedaPharma) / Twitter

Global Twitter channel for Takeda. ... 70+ countries takeda.com Joined June 2009 ... From protein subunit to mRNA vaccines, there are different types of ...

#97. Will I have more serious illness if I get dengue a second time?

Q: Are there any vaccines against dengue and are they safe? ... She added that clinical trials of a vaccine by pharmaceutical giant Takeda ...